This report was first published by Endpoints News. To see the original version, click here
Sanofi is double-dipping with AI-driven biologics developer Earendil Labs in a deal worth up to $160 million in upfront and near-term checks.
The agreement, carrying a total potential value of $2.56 billion, is the second between the two companies. The French pharma giant and the Delaware startup teamed up for $125 million upfront last April on two bispecific antibodies for autoimmune and inflammatory bowel diseases.
您已阅读34%（509字），剩余66%（988字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。